Question 1

What is the difference between Trulicity and Zepbound?

Accepted Answer

Both are Eli Lilly weekly injections, but they are really very different drugs. Trulicity is dulaglutide, a single-receptor GLP-1 agonist FDA-approved for type 2 diabetes and cardiovascular risk reduction in diabetes patients. Zepbound is tirzepatide, a dual GIP and GLP-1 receptor agonist FDA-approved for chronic weight management and obstructive sleep apnea in adults with obesity. Trulicity tops out at 4.5 mg weekly; Zepbound goes up to 15 mg. The molecules, mechanisms, maximum doses, and insurance pathways are all different. Tirzepatide is also sold as Mounjaro for type 2 diabetes, while Trulicity only exists for the diabetes indication.

Question 2

Which causes more weight loss, Trulicity or Zepbound?

Accepted Answer

Zepbound produces far more weight loss — no contest. In SURMOUNT-1, adults on Zepbound 15 mg lost an average of 22.5% of baseline body weight (about 25.3 kg absolute) over 72 weeks, with roughly 63% of participants losing 20% or more. Trulicity users drop around 2 to 3 kg at the 1.5 mg maintenance dose, and 3 to 4 kg at the higher 3 mg and 4.5 mg doses — modest reductions that come as a side benefit of diabetes control rather than the primary goal. The gap reflects both the dual-receptor mechanism of tirzepatide and its dosing strategy for weight management. Trulicity was never engineered to produce Zepbound-scale weight loss.

Question 3

Can I switch between Trulicity and Zepbound?

Accepted Answer

A switch is possible but hinges on your diagnosis and insurance coverage. Trulicity is labeled for diabetes; Zepbound is labeled for weight management and sleep apnea. Moving from Trulicity to Zepbound generally requires meeting Zepbound's prescribing criteria — obesity BMI thresholds or documented OSA — plus a new prior authorization under your plan's weight-management rules. Moving the other way is less common. The mechanics are typical: stop the current drug, wait about a week for it to clear, then start the new one at its lowest dose (Zepbound at 2.5 mg, Trulicity at 0.75 mg) and titrate up. Never stack them. Expect gut symptoms to return during re-titration.

Question 4

Which has fewer side effects, Trulicity or Zepbound?

Accepted Answer

Trulicity is generally gentler on the stomach at typical dose steps. Trulicity shows nausea around 12 to 21%, diarrhea 8 to 13%, and vomiting 6 to 12% across AWARD data. Zepbound shows nausea 24 to 33%, diarrhea 18 to 25%, and vomiting 10 to 18% across SURMOUNT trials — higher across the board, reflecting the more aggressive dose range and longer titration needed for weight management. Both carry the thyroid-tumor boxed warning. Zepbound reports hair shedding in about 5 to 6% of users, tied to rapid weight loss. Slow titration helps either drug. Trulicity's simpler auto- injector device is another edge for patients with needle anxiety or fine motor issues.

Question 5

Is Trulicity or Zepbound cheaper?

Accepted Answer

Costs depend on diagnosis, insurance, and whether you use vials or pens. Sticker prices are comparable in the brand-name GLP-1 range without coverage. For type 2 diabetes, Trulicity is usually covered by commercial plans and Medicare Part D with prior authorization, with typical preferred-tier copays of $25 to $150. Zepbound coverage for weight loss is much more restrictive — many plans exclude weight-loss medications entirely, and Medicare Part D does not cover Zepbound for weight loss alone (though the OSA indication is emerging as a coverage pathway). Eli Lilly offers Zepbound single-dose vials through LillyDirect at reduced self-pay prices roughly $349 to $699 monthly. Savings cards exist for both.

Question 6

Are Trulicity and Zepbound the same drug?

Accepted Answer

No. Same manufacturer (Eli Lilly) but completely different molecules and drug classes. Trulicity is dulaglutide, a GLP-1-only receptor agonist built as a fusion protein with an antibody fragment. Zepbound is tirzepatide, a dual GIP and GLP-1 receptor agonist — it hits two different gut-hormone pathways at once, which is the main reason it produces larger average weight loss than any single-receptor GLP-1. The dose ranges, injection devices, FDA indications, and insurance rules are all separate. They cannot be substituted at the pharmacy. Tirzepatide is also sold as Mounjaro for diabetes — that is the closer comparator to Trulicity for diabetes patients.

Question 7

What does the dual GIP/GLP-1 mechanism in Zepbound do that Trulicity's single action does not?

Accepted Answer

Zepbound activates two gut-hormone receptors — GIP (glucose- dependent insulinotropic polypeptide) and GLP-1 — while Trulicity only activates GLP-1. The combination appears to amplify the appetite-suppressing and metabolic effects beyond what GLP-1 activation alone delivers. In the SURPASS diabetes trials, tirzepatide beat semaglutide on both A1C reduction and weight loss, and in SURMOUNT-5, Zepbound beat Wegovy on weight loss. Mounjaro at the same 15 mg dose produced A1C reductions around 2.3 percentage points versus Trulicity's 1.5 to 1.8 at its top doses. The dual mechanism is widely seen as the reason tirzepatide outperforms GLP-1-only drugs in head-to-head comparisons.

Question 8

If I have diabetes and obesity, is there a way to get both benefits at once?

Accepted Answer

Yes, and this is actually a common scenario. For patients with both type 2 diabetes and obesity, many prescribers consider Mounjaro (same active ingredient as Zepbound — tirzepatide — but labeled for diabetes) rather than trying to combine Trulicity with Zepbound. Taking two GLP-1-class drugs at once is not recommended. Mounjaro delivers strong A1C reduction and substantial weight loss from a single prescription, and insurance coverage for diabetes is typically less restrictive than for weight-management indications. Wegovy is another option when weight is the main concern. Your endocrinologist or primary care physician can match the right product to your diagnosis and coverage situation.

Feature	Trulicity(dulaglutide)	Zepbound(tirzepatide)
Active Ingredient	dulaglutide	tirzepatide
Drug Class	GLP-1 receptor agonist	Dual GIP and GLP-1 receptor agonist
Manufacturer	Eli Lilly	Eli Lilly
FDA Approved	2014-09-18	2023-11-08
Approved Indications	Type 2 diabetes mellitus (adjunct to diet and exercise) Reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors	Chronic weight management in adults with BMI ≥30 or ≥27 with at least one weight-related comorbidity (adjunct to diet and exercise) Treatment of moderate-to-severe obstructive sleep apnea in adults with obesity (December 20, 2024)
Route	subcutaneous injection	subcutaneous injection
Frequency	Once weekly	Once weekly
Starting Dose	0.75 mg weekly	2.5 mg weekly
Maintenance Dose	1.5 mg weekly	5 mg, 10 mg, or 15 mg weekly
Max Dose	4.5 mg weekly	15 mg weekly
Weight Loss (%)	3.1%	22.5%
A1C Reduction	1.5%	N/A (not indicated for diabetes)
Key Trial	REWIND (260 weeks)	SURMOUNT-1 / SURMOUNT-5 (head-to-head vs semaglutide) (72 weeks)
List Price	$950-$1,100/month	$1,060-$1,176/month
With Insurance	$25-$150/month (varies by plan)	$25-$250/month (varies; weight-loss coverage is limited)
Savings Card	$25/month (Lilly savings card, commercially insured)	$25/month (Lilly savings card, commercially insured)

Side Effect	Trulicity	Zepbound
Nausea	12-21%	24-33%
Diarrhea	8-13%	18-25%
Vomiting	6-12%	10-18%
Abdominal pain	6-9%	10-14%
Decreased appetite	4-9%	Not reported
Dyspepsia	4-6%	7-10%
Fatigue	4-6%	Not reported
Pancreatitis (rare)	<0.5%	<1%
Constipation	Not reported	13-17%
Injection site reaction	Not reported	3-7%
Hair loss	Not reported	5-6%
Gallbladder events	Not reported	1.6%

Trulicity vs Zepbound

Summary

Trulicity vs Zepbound: Full Comparison

Side Effects: Trulicity vs Zepbound

Related Comparisons

Frequently Asked Questions

Sources & References

FDA & Regulatory

Clinical Trial Records

Peer-Reviewed Literature

Safety Communications

Manufacturer Information

Reference Entries

Additional References